查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557318

自我血糖监测设备 (SMBG) 的全球市场 - 2024 年至 2029 年预测

Global Self-Monitoring Blood Glucose (SMBG) Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

自我血糖监测设备（SMBG）市场预计将从2024年的116.44亿美元成长到2029年的158.83亿美元，成长率为6.41%（CAGR）。

自我血糖监测 (SMBG) 装置可监测一个人的血糖浓度。高血糖和低血糖都会对人体产生严重影响，因此定期检查是必要的。糖尿病是一种慢性疾病，会破坏人体分泌胰岛素的能力，对整体健康和其他器官的功能产生负面影响。

由于复杂、压力大的生活方式和工作文化导致不良的饮食习惯，糖尿病病例数量不断增加，因此有必要定期检查体内的胰岛素，特别是对于患有糖尿病的人来说。 SMBG 设备是可携式、快速的合成设备，可在几分钟内提供血液中的血糖浓度，因此在监测血糖方面得到更广泛的采用。

市场技术进步在推动市场成长方面也发挥着重要作用。此外，医疗保健支出的增加预计将推动市场。

自我血糖监测设备（SMBG）市场驱动因素：

  • 由于生活方式复杂化和饮食摄取不准确，糖尿病患者数量不断增加，推动了市场的成长。

试纸和血糖仪等自我血糖测量设备在改善患者代谢控制和药物治疗方面发挥重要作用，可以清楚地了解患者的血糖状况。此外，SMBG 设备提供的必要资讯将帮助医生了解患者的饮食摄取量以及根据健康状况开出哪些药物。

根据国际糖尿病联盟预测，到2030年，全球将有近6.43亿人患有糖尿病，到2045年，全球将有近7.83亿人患有糖尿病。

随着糖尿病人口的惊人增长，自我血糖监测设备的需求预计在未来几年将强劲增长。这在新兴经济体尤其明显，这些低度开发国家，刺激了整体市场的扩张。

  • 宣传糖尿病意识的宣传活动和倡议

糖尿病是全世界主要的健康问题之一，会引起与眼睛、脚和肾臟相关的各种健康问题。因此，正在实施各种健康宣传活动和政府支持的倡议，以减少此类疾病的传播。例如，2023 年 2 月，纽约州卫生部发起了一项宣传宣传活动，鼓励在西班牙裔和黑人社区进行糖尿病前期检测。

同样，根据 2024 年 6 月 7 日的新闻稿，英格兰国家医疗服务体系宣布，将于 6 月 10 日起在西米德兰兹郡举办糖尿病宣传週。此类措施和宣传活动可能会将人们的注意力转移到自我监测血糖水平上，并增加对 SMBG 设备的需求。

自我血糖监测设备（SMBG）市场細項分析

  • 试纸预计将占据重要的市场占有率

根据产品类型，全球自助血糖仪市场分为血糖仪、试纸、采血针和采血笔。另一方面，试纸是一次性的、一次性使用的试纸，上面放置有血液，以便可以将其註射到血糖仪中。试纸由于是一次性的而占据了很大的市场占有率。

血糖仪是一种电子设备，它使用透过试纸注入的血液样本来计算和显示血糖值。因此，它在市场上占有很大的份额。

  • 据估计，2 型糖尿病占了很大的市场占有率。

根据指示，全球自我血糖仪市场分为第 1 型糖尿病、2 型糖尿病和妊娠糖尿病。由于 2 型糖尿病在成年人中很常见，并且在各个国家都有很高的盛行率，因此预计其将显着增长并在该疾病中占据很大份额。根据美国疾病管制与预防中心 2023 年 11 月发布的新闻稿，超过三分之一的美国成年人有罹患第 2 型糖尿病的风险。

预计北美在预测期内将占据重要的市场占有率。

从地理来看，SMBG设备市场分为北美、南美、欧洲、中东和非洲以及亚太地区。预计北美地区在预测期内将以有利的速度成长，美国和加拿大等主要区域经济体的糖尿病盛行率不断上升，导致自我血糖监测设备的采用激增。

预计该地区可支配收入的增加和医疗保健支出的增加也将在预测期内推动市场。北美和欧洲的自我血糖测量设备市场预计将占据主要市场占有率。

自我血糖监测设备（SMBG）市场的限制因素

  • 自我监测血糖设备的高成本阻碍了市场的成长。

血糖自我监测设备市场面临的主要限制之一是设备的高成本。自我血糖监测设备包括血糖仪、试纸、采血针和采血器。该设备的初始成本很高。此外，该设备还具有试纸的经常性成本，因为试纸是一次性的且不能重复使用。此类工具的高昂成本可能会限制低收入和中等收入国家的市场。

开拓自我血糖监测设备（SMBG）的主要市场

  • 2023年3月，Asterra Pharma 与 Roche Diabetes Care Japan K.K. 建立合作关係。 2023年3月，Asterra Pharma Co., Ltd.与Roche Diabetcare Japan Co., Ltd.合作开发了一款产品，结合了该公司的血糖仪「Accu-Check® Guide M」与FDA核准的数字健康解决方案「BluStar」 」。我们已经开始在日本市场开发和销售该产品。

2022 年 11 月，Intuity Medical Inc. 和 Embecta Corp. 签订了共同促销协议。 Envector 将利用其经销商在美国市场促销Intuity 的 POGO 自动血糖监测系统。该产品旨在改善糖尿病管理。

自我血糖监测设备（SMBG）市场細項分析如下：

按类型

  • 血糖仪
  • 试纸
  • 采血针和采血笔

按指示

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

按最终用户

  • 医院和诊所
  • 门诊护理设置
  • 诊断中心
  • 居家照护设置

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 日本
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第 5 章按类型分類的全球自我血糖监测设备 (SMBG) 市场

  • 介绍
  • 血糖值仪
  • 试纸条
  • 采血针和采血装置

第六章按适应症分類的自我血糖监测设备（SMBG）的全球市场

  • 介绍
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第七章全球自我血糖监测设备 (SMBG) 市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 门诊就诊环境
  • 诊断中心
  • 家庭护理设置

第 8 章按地区分類的全球自我血糖监测设备 (SMBG) 市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 日本
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Abbott
  • Hoffmann-La Roche Ltd.
  • Lifescan Inc.
  • Bayer Corporation
  • ARKRAY, Inc.
  • B. Braun Melsungen AG
  • Sanofi
  • Ypsomed AG
  • Bionime Corporation
  • Ascensia Diabetes Care Holdings AG
简介目录
Product Code: KSI061612026

The global self-monitoring blood glucose (SMBG) devices market is anticipated to grow from US$11.644 billion in 2024 to US$15.883 billion in 2029 at a 6.41% (CAGR).

A self-monitoring blood glucose (SMBG) device monitors a person's glucose level. Both high and low blood glucose have the potential to severely impact the human body and hence require regular checks. Diabetes is a chronic disease that results in a disturbance in the body's insulin production, negatively impacting overall health and other organs' functioning.

The rising cases of diabetes owing to complex & stressful lifestyles and work cultures that have disturbed the dietary intake of people have created the requirement of recurring insulin checks in the body, especially for those suffering from the disease. SMBG devices are portable, faster, result-yielding devices that provide the glucose level in the blood within a few minutes and hence have witnessed a wider adoption for monitoring glucose.

Technological advancements in the market also play a vital role in encouraging market growth. Furthermore, increasing healthcare expenditures are expected to drive the market.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Drivers:

  • Growing cases of diabetes owing to lifestyle complexities and inaccurate dietary intake have increased the market growth.

Self-monitoring blood glucose devices such as testing strips or glucose meters play an integral in improving a patient's metabolic control, and medication regime and provide a clear picture of their glycemic status. Furthermore, the necessary information provided by the SMBG devices assists doctors in understanding the patient's diet intake and what medications are to be prescribed as per their health status.

Diabetes has been emerging as a problematic chronic disease causing a great threat to life, according to the International Diabetes Federation, by 2030 nearly 643 million people will be living with diabetes globally and by 2045 it will be nearly 783 million.

With the alarming growth of the diabetic population, the demand for self-monitoring blood glucose devices is expected to show massive growth in the coming years. This can be witnessed especially in developed economies, where disposable income is higher than in underdeveloped nations, stimulating the overall market expansion.

  • Favorable campaigns and initiatives to spread awareness against diabetes

One of the major health concerns globally, diabetes leads to various other health problems related to the eyes, feet, and kidneys. Hence, various health campaigns and government-backed initiatives are being implemented to reduce the spread of such diseases. For instance, in February 2023, the New York State Department of Health launched a public awareness campaign to encourage Hispanic and black communities for prediabetic tests.

Likewise, as per the 7 June 2024 press release, the National Health Service England announced diabetic awareness week in West Midland from 10 June, during which the healthcare system will educate people regarding symptoms, risks, and prevention associated with Type 1 and Type 2 diabetes. Such initiatives and campaigns will shift the focus of people towards self-glucose monitoring thereby driving the demand for SMBG devices.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Segment Analysis

  • Testing strips are expected to account for a considerable market share.

Based on product type, the global self-monitoring blood glucose device market is segmented into blood glucose meters, testing strips, and lancets & lancing devices. Testing strips, on the other hand, are disposable, one-time-use strips on which blood is placed so that it can be injected into the blood glucose meter. Since testing strips are single-use, they account for a remarkable market share.

Blood glucose meters are electronic devices that calculate and display blood glucose levels using a sample of blood drops injected through a testing strip. Hence, they have a significant share of the market.

  • Type 2 diabetes is estimated to account for a considerable market share.

Based on indication, the global self-monitoring blood glucose device market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 2 diabetes is poised for remarkable growth and will constitute a remarkable share as such diseases are found more commonly in adults and have a high prevalence in countries. According to the November 2023 press release of the Center for Disease Control and Prevention, more than 1 in 3 American adults are at risk of developing type 2 diabetes.

North America is predicted to constitute a considerable market share during the forecast period.

Geographically, the SMBG device market is divided into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific regions for the study. North America is expected to grow at a lucrative rate during the forecasted period, fuelled by the growing prevalence of diabetes in major regional economies, namely the United States and Canada, which has surged the adoption of self-monitoring blood glucose devices.

Rising disposable income and increasing expenditure on healthcare in the region are also expected to drive the market during the forecast period. The North American and European self-monitoring blood glucose device markets are projected to hold a large market share.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Restraints

  • The high associated cost of self-monitoring blood glucose devices will hinder market growth.

One of the prime constraints facing the self-monitoring blood glucose device market is the significant cost of the device. Self-monitoring blood glucose devices involve blood glucose meters, testing strips, and lancets and lancing devices. The initial cost of this device is significant. Furthermore, the device has a recurring cost of testing strips since these strips are single-use and cannot be reused. The notable cost of such a device has the potential to constrain the market in lower-middle and lower-income countries.

Global Self-Monitoring Blood Glucose (SMBG) Devices Key Market Developments

  • In March 2023, Astella Pharma Inc. partnered with Roche Diabetes Care Japan Co. Ltd to bolster the development & commercialization of the former's "Accu-Chek(R) Guide M" blood glucose monitoring system as a combined product with FDA-approved digital health solution "BluStar" in the Japanese market.

In November 2022, Intuity Medical Inc. and Embecta Corp. formed a co-promotional agreement. The latter would use its sales representatives to promote Intuity's "POGO Automatic(R) Blood Glucose Monitoring System" in the US market. The product aims to improve people's diabetes management.

The Global Self-Monitoring Blood Glucose (SMBG) Devices market is segmented and analyzed as follows:

By Type

  • Blood Glucose Meters
  • Testing Strips
  • Lancets & Lancing Device

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By End-User

  • Hospitals and Clinics
  • Ambulatory Care Settings
  • Diagnostics Centers
  • Home Care Settings

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Blood Glucose Meter
  • 5.3. Testing Strips
  • 5.4. Lancets & Lancing Devices

6. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY INDICATION

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes
  • 6.3. Type 2 Diabetes
  • 6.4. Gestational Diabetes

7. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Ambulatory Care Settings
  • 7.4. Diagnostics Centers
  • 7.5. Home Care Settings

8. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. South Korea
    • 8.6.4. Taiwan
    • 8.6.5. Thailand
    • 8.6.6. Indonesia
    • 8.6.7. Japan
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Hoffmann-La Roche Ltd.
  • 10.3. Lifescan Inc.
  • 10.4. Bayer Corporation
  • 10.5. ARKRAY, Inc.
  • 10.6. B. Braun Melsungen AG
  • 10.7. Sanofi
  • 10.8. Ypsomed AG
  • 10.9. Bionime Corporation
  • 10.10. Ascensia Diabetes Care Holdings AG